Microbot Medical (FRA:CY9D) Tariff Resilience Score: 4/10 (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CY9D Microbot Medical Inc FRA:CY9D
36 GF Score
Price €1.54
! 2 Warning Signs
View Full Analysis

What is Microbot Medical Tariff Resilience Score?

Microbot Medical FRA:CY9D -0.65% 36 Tariff Resilience Score is 4 as of Jul. 23, 2026. GuruFocus rates FRA:CY9D with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 832 Medical Devices & Instruments companies, Microbot Medical ranks better than 70.07% on this metric.

Microbot Medical has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Microbot Medical has Medical device company with global supply chains. Vulnerable to tariffs on imported components, but can mitigate through alternative suppliers and potential industry-specific exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Microbot Medical might have Average Resilient.

Microbot Medical  (FRA:CY9D) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Microbot Medical Tariff Resilience Score Related Terms

FRA:CY9D vs STXS, POCI, DXR: Tariff Resilience Score Comparison

For the Medical Instruments & Supplies subindustry, Microbot Medical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microbot Medical Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Microbot Medical's Tariff Resilience Score falls into.


FRA:CY9D
36GF Score
Microbot Medical Inc FRA:CY9D
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Microbot Medical (FRA:CY9D) has a Tariff Resilience Score of 4 as of Jul. 23, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Microbot Medical ranks #249 out of 832 companies in the Medical Devices & Instruments industry, placing it in the top 29.9%.
Is Microbot Medical's Tariff Resilience Score too high?
Microbot Medical's current Tariff Resilience Score is 4. Based on the distribution chart, Microbot Medical ranks #249 out of 832 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Microbot Medical has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's Tariff Resilience Score compare to STXS and POCI?
According to the Medical Devices & Instruments industry distribution chart, Microbot Medical ranks #249 out of 832 companies for Tariff Resilience Score. This puts Microbot Medical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Microbot Medical's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (FRA:CY9D) has a current Tariff Resilience Score of 4. The current Tariff Resilience Score is 4. Microbot Medical's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Microbot Medical (FRA:CY9D), the current Tariff Resilience Score is 4 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microbot Medical Business Description

Other Exchanges MBOT:USA
Address 175 Derby Street, Building 27, Hingham, MA, USA, 02043
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
36GF Score

Get the complete analysis for FRA:CY9D

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54
Price